Yttrium Y 90 Glass Microspheres and Capecitabine in Treating Patients With Liver Cholangiocarcinoma or Liver Metastases
Status:
Completed
Trial end date:
2014-07-08
Target enrollment:
Participant gender:
Summary
RATIONALE: Radiation therapy uses high-energy x-rays and other types of radiation to kill
tumor cells. Specialized radiation therapy, such as yttrium Y 90 glass microspheres that
deliver a high dose of radiation directly to the tumor, may kill more tumor cells and cause
less damage to normal tissue. Drugs used in chemotherapy, such as capecitabine, work in
different ways to stop the growth of tumor cells, either by killing the cells or by stopping
them from dividing. Capecitabine may also make tumor cells more sensitive to radiation
therapy.
PURPOSE: This phase I trial is studying the side effects and best dose of yttrium Y 90 glass
microspheres when given together with capecitabine in treating patients with liver
cholangiocarcinoma or liver metastases.